1. Treatment outcome, toxicity, and predictive factors for radioligand therapy with (177)Lu-PSMA-I&T in metastatic castration-resistant prostate cancer;Heck;Eur Urol,2019
2. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study;Hofman;Lancet Oncol,2018
3. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.1, 2019, AWMF Registernummer: 043/022OL. http://www.leitlinienprogramm-onkolo-gie.de/leitlinien/prostatakarzinom/.
4. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients;Rahbar;J Nucl Med,2017
5. Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 ((177)Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer;Violet;J Nucl Med,2020